Latest news with #bioprinting
Yahoo
10-08-2025
- Business
- Yahoo
3D Systems Corporation (DDD) Retires $88 Million in Debt; Its 3D bioprinted, bioabsorabable Nerve Repair Device Receives FDA Approval
3D Systems Corporation (NYSE:DDD) is included in our list of the 10 Best AI Stocks to Buy Under $3. On June 24, 2025, 3D Systems Corporation (NYSE:DDD) successfully restructured its debt, retiring $88 million in debt, issuing new notes maturing in 2030, and repurchasing 8 million shares to reduce dilution. With this move, the company aims to enhance its financial flexibility. Meanwhile, on June 26, 2025, 3D Systems Corporation (NYSE:DDD) achieved a critical medical breakthrough. Its 3D bioprinted, bioabsorbable nerve repair device, developed in partnership with TISSIUM, received FDA approval. This regulatory approval strengthens the company's leadership in regenerative medicine, following years of innovation in printing living tissues. Therefore, 3D Systems Corporation (NYSE:DDD) is well-positioned to redefine the possibilities of additive manufacturing with its strong balance sheet and ongoing progress in healthcare. With the help of its AI-driven software, 3D Systems Corporation (NYSE:DDD) delivers precision additive manufacturing solutions, serving aerospace, healthcare, materials, and bioprinting segments. It is included in our list of the best AI stocks. While we acknowledge the potential of DDD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Cheap Value Stocks to Buy Now According to Warren Buffett and 7 Best Potash Stocks to Buy According to Analysts. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
05-08-2025
- Business
- Yahoo
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR SECOND QUARTER FINANCIAL RESULTS
REHOVOT, Israel, Aug. 5, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the second quarter on Wednesday, August 20, 2025, before the opening of the U.S. financial markets. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. For more information about CollPlant, visit Contacts: CollPlant:Eran RotemDeputy CEO & CFOTel: +972-73-2325600Email: eran@ Investors:Daniel FerryManaging DirectorLifeSci Advisors, LLCdaniel@ Logo: View original content: SOURCE CollPlant Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
CBC
15-06-2025
- Health
- CBC
Hopes of fatherhood: UBC scientists on frontier of high-tech male infertility research
Social Sharing A team of researchers at the University of British Columbia (UBC) is using artificial intelligence in an effort to detect hard-to-find sperm and 3D bioprinting technology with the ultimate goal of growing sperm in the lab — technologies they say could eventually help men with infertility become parents. The research, led by Dr. Ryan Flannigan, a urologist and associate professor at UBC, is aimed at addressing a "severe form" of male infertility called non-obstructive azoospermia (NOA), in which the body produces little to no sperm. It's a condition that affects about one in 100 men, many of whom are survivors of childhood cancer, according to Flannigan. "There's a big problem with infertility: it's so common," he told CBC's The Early Edition. "Something that I see time and time again is just how much of an emotional toll having challenges with infertility is." According to a UBC media release, about two thirds of male pediatric cancer survivors will face infertility in adulthood, due to the effects of radiation or chemotherapy. Globally, one in six couples struggles to conceive, and male infertility, broadly, plays a role in about half of those cases. AI to detect rare sperm Currently, the only treatment for NOA involves surgically extracting testicular tissue and searching for hard-to-find sperm under a microscope — a tedious process, says Flannigan, that can take hours and still might end in failure. "It's ... looking for a needle in a haystack," he says. "Right now, we're able to find sperm about 50 per cent of the time. We ideally need to find at least one sperm per each egg, among millions of other cells, which takes hours." To improve the odds, Flannigan says he and UBC engineering professor Hongshen Ma have developed an AI-powered tool that scans microscopic images to flag viable sperm for use in in vitro fertilization (IVF). The technology is still a long way from being available for people struggling with male infertility — Flannigan expects clinical trials for the AI tool could begin within the next three to five years. Lab-grown sperm for those without options But for people who produce no sperm at all, including children who undergo cancer treatment before puberty and are unable to store sperm, a more experimental avenue is underway: lab-grown sperm. In what the UBC media release calls a world-first, Flannigan and team have bioprinted a model of human testicular tissue using stem cells and a specialized gel-like "bio-ink." The printed structure replicates the tiny tubes in the testes where sperm are normally produced. These bioprinted 'mini testicles' are encased in a special gel filled with specific nutrients and vitamins to help them mature. According to researchers, some of the cells have already begun showing signs consistent with the early stages of puberty — "a time when sperm production starts occurring in the human body." "What we're trying to do with 3D bioprinting is recreate what's happening in a healthy testicle as accurately as we can," said Flannigan. "If we can determine what the cells need to progress through all the phases of sperm production, we can use that knowledge to figure out how to create sperm for a patient with NOA," says Dr. Flannigan. The work is being supported by experts in microfluidics — a system that manipulates a small amount of fluids — and cancer biology at UBC and the University of Victoria, who are helping identify the molecular conditions required for sperm to develop. Still, researchers acknowledge there are significant challenges ahead. According to the UBC release, sperm production is a "highly complicated process" involving multiple cell types, complex anatomical structures, making it a task that demands collaborative, multidisciplinary research. 'Life-changing' potential, but questions remain Laura Spencer, a fertility coach in Vancouver, has experienced the emotional toll of infertility first-hand in her own family. "I've gone through infertility — male factor infertility in particular — and it's devastating," she told CBC News. "There's nothing quite like it." She said this latest development in treating male infertility could potentially be life-changing for many couples. WATCH | An at-home test is in the works to measure male fertility: An at-home test is in the works to measure male fertility 3 months ago Duration 1:46 Researchers at the University of Waterloo are working on an at-home test, which is a cheaper alternative to other tests. It usually involves examining the sperm under a microscope in a lab, but this one will allow people to check right at home. Sushanta Mitra, a professor of mechanical and mechatronics engineering, is one of the researchers behind the study. "This shows a lot of promise for people who might not have the ability to try and conceive … they might actually be able to have a baby." Spencer says male infertility remains a taboo subject, despite being a factor in about half of all couples struggling to conceive. She hopes this research not only opens new medical doors, but also breaks down stigma. "There is a lot of shame and sometimes guilt around that," she said. "I'm always grateful when the conversation turns to infertility and when it's normalized." "There will definitely need to be education around this," she added. "We don't know what the long term consequences are of this technology. Are there any birth defects that are possible? What about when they grow up? Like we don't know. This is just so new." As for concerns about the safety of AI or stem cell-based procedures, Flannigan says the research team is taking a cautious approach.
